Overview

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Status:
Completed

Trial end date:
2018-04-04

Target enrollment:

Participant gender:

Summary

This is a Phase III randomized, double-blind, parallel group, multi-center, 52-week COPD exacerbation and lung function study with PT009 320/9.6 μg, PT009 160/9.6 μg and PT005 9.6 μg, all administered BID.

Phase:

Phase 3

Details

Lead Sponsor:

Pearl Therapeutics, Inc.

Treatments:

Budesonide
Formoterol Fumarate